Millennium Pharmaceuticals Limited

Eli Lilly and Company

John J G Mullins

James P Kanter

Robert M Scarborough

Anjali Pandey

Gerd Ruhter

Barbara S Briggs

Uko Effiong Udodong

Derek Walker

Milton Zmijewski, Jr

Daniel Verral, Ii

Thomas Hense

Novel processes for producing enantiomerically enriched and enantiomerically pure compositions of 2-acyl substituted chromane compounds, and 2-acylchromane compounds that are intermediates for producing platelet aggregation inhibitors and/or are themselves potent platelet aggregation inhibitors are disclosed. Further disclosed are processes for producing salts such as acid addition salts for such enantiomerically enriched compositions.

Synthesis of 2-acyl substituted chromanes and intermediates thereof

Disclosed are processes for producing chromane compounds, preferably chroman-2-yl acetic acid compounds and 6-amino-chroman-2-yl acetic acid esters which are intermediates for producing platelet aggregation inhibitors and/or are themselves potent platelet aggregation inhibitors.

Methods for producing amino substituted chromanes and intermediates thereof

Disclosed are process steps and novel processes for producing chromane compositions enriched in at least one (2R or 2S) enantiomer, preferably chroman-2-yl carboxylic acid compounds and chroman-2-yl carboxylic acid esters which are intermediates for producing platelet aggregation inhibitors and/or are themselves potent platelet aggregation inhibitors. Further disclosed are enzymatic processes for resolving chiral intermediates or final products to provide desired enantiomers.

Methods for producing chiral chromones, chromanes, amino substituted chromanes and intermediates therefor

Growing community of inventors

San Francisco, CA, United States of America

John J G Mullins